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Abstract  
 
Aim:  To comprehensively compare the prognostic value of tumour and patient-related 
factors in patients undergoing curative surgery for colon cancer.   
Methods:  From a database of 287 patients who underwent elective resection between 1997-
2005, tumour factors including stage and host factors including systemic inflammatory 
response (modified Glasgow Prognostic Score (mGPS)) were identified. 
Results:  Median follow-up was 65 months.  Over this time period 125 patients died, 80 from 
cancer.  On multivariate analysis of all significant patient and tumour related factors, Dukes 
stage (P<0.01), vascular invasion (P<0.01), and the mGPS (P<0.01) were independently 
associated with cancer-survival.  Of the patient-related factors, age (P<0.01), haemoglobin 
(P<0.01), white-cell (P<0.01), neutrophil (P<0.01) and platelet (P<0.01) counts and alkaline 
phosphatase (P<0.01) were most significantly associated with the mGPS.  
Conclusion:  In addition to tumour-related factors such as Dukes stage and vascular invasion, 
the pre-operative mGPS should be included to guide prognosis in patients undergoing curative 
resection for colon cancer. 
Introduction: 
Colorectal cancer remains the second most common cause of cancer death in Western 
Europe and North America.  Each year, in the UK, the disease accounts for over 16,000 
deaths with 35,000 new cases 1.  Colon cancer accounts for majority of disease with 
approximately 22,000 new cases and over 10, 000 deaths per year 1. Overall survival remains 
poor with only 60% of those patients undergoing resection with curative intent surviving 5 
years 2. 
Following curative resection for colon cancer, pathological analysis for tumour related 
factors guides prognosis and provision of adjuvant therapy.  A variety of high risk features 
including tumour stage, nodal status, the ratio of metastatic to examined lymph nodes and 
presence or absence of venous invasion are considered to be important in planning adjuvant 
therapy and follow-up 3-7.   
However, it is also now recognised that cancer outcomes are not solely determined by 
tumour-related factors but also by patient-related factors 8 9.  Indeed, the presence of a pre-
operative systemic inflammatory response, as evidenced by a simple objective score 
(modified Glasgow Prognostic Score (mGPS) based on circulating levels of two acute phase 
proteins, C-reactive protein and albumin, is independently associated with poor cancer 
outcomes in patients undergoing surgery for colon and rectal cancer 10 11 12.   
The acute phase protein response is only one aspect of the systemic inflammatory 
response 13.  Previous work has also identified a significant relationship between cellular 
components of the pre-operative systemic inflammatory response including white cell, 
neutrophil, lymphocyte, monocyte and platelet counts and cancer survival in patients 
colorectal cancer 11 14-19.  Also, the combination of these cellular components such as the 
neutrophil-lymphocyte ratio and the platelet-lymphocyte ratio have been proposed to have 
prognostic value 20-22. 
The systemic inflammatory response, as evidenced by the mGPS, also appears to be 
associated with a number of routine biochemical parameters, in particular alkaline 
phosphatase and γ-glutamyl transferase 23.  Therefore, it of interest that alkaline phosphatase, 
aspartate transaminase and γ-glutamyl transferase have been reported to have prognostic value 
in patients undergoing surgery for colon and rectal cancer 24-29. 
To date, there has been no comprehensive comparison of the prognostic value of 
tumour and patient-related factors, including the systemic inflammatory response.  The aim of 
the present study was to examine the relationship between tumour and patient related factors, 
including the mGPS, and cancer specific survival in patients under going potentially curative 
surgery for colon cancer.   
Materials and methods 
 Patients with histologically proven colon cancer who, on the basis of laparotomy 
findings and pre-operative abdominal computed tomography, were considered to have 
undergone potentially curative resection between January 1997 and July 2005 in a single 
surgical unit, were included in the study.  Patients were identified from a prospectively 
maintained colorectal cancer database.  Exclusion criteria were: (i) emergency surgery (ii) 
death within 30 days of surgery (iii) clinical evidence of infection or other inflammatory 
conditions such as inflammatory bowel disease or rheumatoid arthritis.  Tumours were staged 
using the conventional Dukes classification 30. 
 Pathological details were obtained from reports issued following tumour resection. 
The lymph node ratio was calculated by dividing the number of metastatic lymph nodes 
identified by the total number of lymph nodes sampled.  In the present study, cut offs of 0.25 
and 0.5 were used to stratify patients as high or low risk within the Stage III or node positive 
patients as previously described 31 32.  Routine laboratory measurements for haemoglobin, 
white cell, neutrophil, lymphocyte, platelet counts, bilirubin, aspartate transaminase, alanine 
transaminase, γ-glutamyl transferase, alkaline phosphatase, adjusted calcium, globulins, 
albumin and C-reactive protein concentration prior to surgery were recorded. 
The calcium concentrations were adjusted for albumin using the formula: adjusted 
calcium = measured calcium + ((43-measured albumin) x 0.07.  Coefficient of variation for 
these methods, over the range of measurement, was less than 10% as established by routine 
quality control procedures. 
The GPS was constructed as previously described 33.  Briefly, patients with both an 
elevated C-reactive protein (>10mg/l) and hypoalbuminaemia (<35g/l) were allocated a score 
of 2.  Patients in whom only one of these biochemical abnormalities was present were 
allocated a score of 1.  Patients in whom neither of these abnormalities was present were 
allocated a score of 0.  Recently, however, this has been modified based on evidence that 
hypoalbuminaemia, in patients with colorectal cancer without an elevated C-reactive protein 
concentration, had no significant association with cancer specific survival.  Therefore, 
patients with an elevated C-reactive protein were assigned a modified GPS score (mGPS) of 1 
or 2 depending on the absence or presence of hypoalbuminaemia 10. 
The provision of adjuvant chemotherapy following surgery was at the discretion of the 
medical or clinical oncologists present at multi-disciplinary assessment.  All clinical and 
pathological data, including co-morbidities, were available to the oncologist in making these 
decisions and the treatment offered was based on the treatment guidelines for colon cancer at 
that time. 
 The study was approved by the Research Ethics Committee, Royal Infirmary, 
Glasgow. 
 
Statistics 
Grouping of the variables was carried out using standard thresholds for laboratory 
parameters 11 34-37.  The relationships between the mGPS and other variables were analysed 
using the Mantel–Haenszel (X2) test for trend as appropriate.  Deaths up to August 2008 were 
included in the analysis.  Univariate survival analysis was performed using the Kaplan–Meier 
method with the log-rank test.  Multivariate survival analysis, including all significant 
covariates was performed using a stepwise backward procedure to derive a final model of the 
variables that had a significant independent relationship with survival.  To remove a variable 
from the model, the corresponding P-value had to be greater than 0.05.  Because of the 
number of statistical comparisons, a P value of <0.01 was considered to be significant.  
Analysis was performed using SPSS software (SPSS Inc., Chicago, IL, USA). 
Results 
Two hundred and eighty seven patients undergoing elective potentially curative 
resection for colon cancer were studied.  All pathological data and criteria for the mGPS were 
available in all 287 patients.  Biochemistry including full liver function testing was available 
for 224 patients.  Pre-operative haematology results were available for 167 patients.  
The tumour characteristics and relationships with overall and cancer specific survival 
are shown in Table 1.  The majority of patients had Dukes A/B disease (59%), moderate to 
well differentiated tumours (86%), had no evidence of vascular invasion (65%), no evidence 
of peritoneal involvement (71%), clear surgical margins (90%), no evidence of tumour 
perforation (96%), no evidence of perineural invasion (93%), a lymph node ratio of 0 (59%) 
and 12 or more lymph nodes sampled (63%).  Median number of lymph nodes sampled was 
14 (range 2-52).  Sixty patients (21%) received adjuvant chemotherapy (Table 1). 
The patient related characteristics and relationships with overall and cancer specific 
survival are shown in Table 2.  The majority of patients were 65 years or older (70%), male 
(54%).  The majority of patients had pre-operative total white cell counts (59%), neutrophil 
counts (82%), lymphocyte counts (92%) and platelet counts (73%) in the normal range.  
Therefore, the majority of patients had a neutrophil/ lymphocyte ratio (77%) and platelet/ 
lymphocyte ratio (76%) within the normal range (Table 2).  The majority of patients had a 
pre-operative bilirubin (96%), aspartate transaminase (99%), alanine transaminase (99%), γ-
glutamyl transferase (79%) and alkaline phosphatase (55%) within the normal range.  The 
majority of patients had globulin (94%), adjusted calcium (97%) and mGPS (57%) within the 
normal range (Table 2). 
 The median follow-up for survivors was 65 months (minimum 36 months).  Over this 
period one hundred and twenty-five patients died, eighty-one from their cancer.  On 
univariate survival analysis of tumour-related factors, Dukes stage (P<0.001), extramural 
vascular invasion (P<0.001), peritoneal involvement (P<0.01), margin involvement (P<0.001) 
and increasing lymph node ratio (P<0.001) were significantly related to cancer specific 
survival (Table 1). 
 On univariate survival analysis of patient-related characteristics, age (P<0.001), white 
cell count (P<0.01) and the mGPS (P<0.001) were significantly related to cancer specific 
survival (Table 2). 
 On multivariate analysis of significant tumour and patient related factors, Dukes stage 
(HR 3.01, 95% CI 1.50-6.06, P=0.002), extramural vascular invasion (HR 3.16, 95% CI 1.53-
6.58, P=0.002), and the mGPS (HR 1.96, 95% CI 1.19-3.21, P=0.008) were independently 
related to cancer specific survival (Table 3).  
 The relationships between an increasing mGPS and patient related factors are shown 
in Table 4.  An increased mGPS was associated with increased age (P<0.001), lower 
haemoglobin (P<0.001), increased white cell (P<0.001), neutrophil (P<0.001) and platelet 
(P<0.001) counts and increased neutrophil/lymphocyte ratio >5:1 (P<0.001) and increased 
alkaline phosphatase (P<0.001).   
 
Discussion 
In the present study, in addition to Dukes stage, the most important tumour-related 
factors associated with cancer specific survival was extramural vascular invasion.  These 
results are consistent with current guidelines, which identify patients undergoing potentially 
curative resection for colon cancer at high risk of recurrence 3-7. 
In the present study, the mGPS was the most important patient-related factor 
associated with cancer specific survival.  These results are consistent with previous studies 
confirming the role of the mGPS in primary operable colon and rectal cancer 10 12.  Ishizuka 
and colleagues 12 have called for the ‘worldwide adoption of the GPS for postoperative 
prognostication of patients with colon and rectal cancer”.   
Recently, in addition to the Glasgow Prognostic Score, a variety of inflammation-
based scores have been developed to predict cancer specific survival in patients with primary 
operable gastrointestinal cancer, including the neutrophil/ lymphocyte ratio and the platelet 
lymphocyte ratio 20-22.  In the present study, neither the neutrophil/ lymphocyte ratio nor the 
platelet/ lymphocyte ratio were significantly associated with cancer specific survival.  
Therefore, these new scores based on the cellular components of the systemic inflammatory 
response cannot be recommended for routine use in predicting survival in patients undergoing 
potentially curative resection for colon cancer. 
In the present study, in addition to the cellular components of the systemic 
inflammatory response, alkaline phosphatase was directly associated with the mGPS.  These 
results are consistent with those previously reported in patients with advanced lung and 
gastrointestinal cancer 23.  Given that circulating concentrations of enzymes primarily reflect 
that synthesised by the liver in response to systemic inflammation, this increased functional 
requirement may be important for regulating other enzyme activity in the liver.  For example, 
it has recently been reported that cytochrome P450 3A4 activity is reduced as part of the 
systemic inflammatory response in patients with advanced cancer 38.  This mechanism may 
account for the observation that a raised mGPS is associated with a poor tolerance to 
chemotherapy in patients with colorectal cancer 39 40.  Irrespective of the mechanisms 
involved the results of this study indicate that, along with its prognostic value, the mGPS is 
associated with a cluster of cellular and biochemical changes in patients undergoing 
potentially curative resection for colon cancer. 
In the present study neither CEA or CA-19-9, proposed tumour markers were 
measured prior to surgery.  There is some evidence that the combination of pre-operative 
serum CEA and CA-19-9 have independent prognostic value in patients undergoing resection 
for colorectal cancer 41.  However, Ishizuka and coworkers 12 recently reported that, compared 
with tumour markers such as CEA, CA 19-9 and CA 72-4, the mGPS had superior prognostic 
value.  Further work is required to determine whether a combination of tumour markers offers 
prognostic value in addition to pathological staging and the mGPS. 
The results of the present study add further evidence to the importance of the systemic 
inflammatory response and the prognostic value of the mGPS in patients with colon cancer 10-
12 42
.  Therefore, the mGPS has the potential to aid detection of early tumour recurrence 
following surgery.  In contrast, the role of the mGPS in predicting response to neoadjuvant or 
adjuvant chemotherapy is less clear.  There are some recent reports from other centres that 
suggest that the mGPS might be useful in predicting response to chemotherapy 12 40 43.  This is 
of particular interest given a recent report from the UK National Confidential Enquiry into 
Patient Outcome and Death (NCEPOD) which concluded that chemotherapy had probably 
hastened or caused death, in over a quarter of patients who died within 30 days of receiving 
treatment 44.  They suggest therefore, that greater caution be used in prescribing chemotherapy 
in very sick patients 44.  However, they do not suggest how this problem might be avoided or 
how the very sick patients are to be identified.  Therefore, the mGPS has also the potential to 
guide the selection of chemotherapy for colorectal cancer patients.  However, the impact of 
using the mGPS as a therapeutic target has as yet not been explored. 
In summary, both tumour-related and patient-related factors are important predictors 
of survival in patients undergoing potentially curative resection of colon cancer.  In addition 
to tumour stage, and vascular invasion, the systemic inflammatory response, as evidenced by 
the mGPS, should be included in the routine clinical assessment, planning of treatment and 
the stratification of randomized trials of patients with colon cancer. 
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Table 1:  The relationship between tumour related factors and overall survival and cancer 
specific survival in patients undergoing potentially curative resection for colon cancer 
 
  Overall survival  Cancer Specific Survival 
 
 
Patients 
n=287 (%) 
5 year 
survival rate 
% (SE) 
P value 
(log rank) 
5 year 
survival rate 
%(SE) 
P value 
(log rank) 
Dukes Stage   A 
                       B 
                       C 
19 (7) 
149 (52) 
119 (41) 
88 (4) 
68 (5) 
48 (5) 
 
 
<0.001 
85 (8) 
85 (4) 
65 (5) 
 
 
<0.001 
Differentiation      Mod-well 
                              Poor 
248 (86) 
39 (13) 
64 (3) 
43 (8) 
 
0.017 
78 (3) 
70 (9) 
 
0.171 
Extramural vascular invasion 
                              Absent 
                              Present 
 
188 (65) 
19 (35) 
 
69 (4) 
45 (5) 
 
 
<0.001 
 
84 (3) 
62 (6) 
 
 
<0.001 
Peritoneal involvement 
                              Absent 
                              Present 
 
205 (71) 
82 (29) 
 
65 (4) 
52 (6) 
 
 
0.021 
 
83 (3) 
62 (7) 
 
 
0.006 
Margin involvement 
                              Absent 
                              Present 
 
259 (90) 
28 (10) 
 
64(3) 
32 (9) 
 
 
<0.001 
 
79 (3) 
33 (16) 
 
 
<0.001 
Tumour perforation 
                              Absent 
                              Present 
 
276 (96) 
11 (4) 
 
62 (3) 
27 (13) 
 
 
0.002 
 
78 (3) 
20 (24) 
 
 
0.018 
Perineural invasion 
                              Absent 
                              Present 
 
268 (93) 
19 (7) 
 
62 (3) 
39 (12) 
 
 
0.113 
 
81 (3) 
46 (11) 
 
 
0.042 
Lymph nodes sampled 
                              >12 
                              <12 
 
180 (63) 
107 (37) 
 
63 (4) 
57 (5) 
 
 
0.288 
 
80 (4) 
70 (6) 
 
 
0.848 
Lymph Node Ratio   0 
                                 0.01-0.24 
                                 0.25-0.49 
                                  >0.5 
166 (59) 
78 (27) 
32 (11) 
11 (4) 
70 (4) 
51 (6) 
59 (9) 
9 (9) 
 
 
 
<0.001 
86 (3) 
60 (6) 
61 (9) 
21 (13) 
 
 
 
<0.001 
Adjuvant chemotherapy   
                              Yes 
                              No 
 
60 (21) 
227 (79)  
 
58 (3) 
71 (6) 
 
 
0.059 
 
80 (3) 
69 (7) 
 
 
0.972 
Table 2: The relationship between patient related factors and overall survival and cancer 
specific survival in patients undergoing potentially curative resection for colon cancer. 
  Overall Survival Cancer Specific Survival 
 
 
Patients  
n=287 % 
5 year 
survival rate 
% (SE) 
P value 
(log rank) 
5 year 
survival rate 
% (SE) 
P value 
(log rank) 
Age  <65 years 
        65-74years 
        >75years 
85 (30) 
87 (30) 
115 (40) 
82 (4) 
66 (5) 
42 (5) 
 
 
<0.001 
86 (4) 
75 (5) 
62 (5) 
 
 
<0.001 
Sex  Female 
        Male 
133 (46) 
154 (54) 
58 (4) 
63 (4) 
 
0.474 
74 (4) 
73 (4) 
 
0.866 
Haemoglobin 
>13g/d (men) >11.5g/dl (women) 
<13g/dl (men) <11.5g/dl (women) 
 
66 (40) 
101 (60) 
 
66 (6) 
61 (5) 
 
 
0.555 
 
79 (5) 
78 (4) 
 
 
0.671 
White cell count  <8.5x109 
                         8.5-11x109 
                            >11x109 
98 (59) 
45 (27) 
24 (14) 
67 (4) 
69 (7) 
32 (9) 
 
 
0.001 
82 (4) 
82 (6) 
56 (10) 
 
 
0.004 
Neutrophil count  <7.5x109 
                             >7.5x109 
137 (82) 
30 (18) 
66 (4) 
47 (10) 
 
0.055 
81 (4) 
66 (9) 
 
0.051 
Lymphocyte count  >3.0x109 
                                1.0-3.0x109 
                                <1.0x109 
10 (6) 
143 (86) 
14 (8) 
38 (14) 
66 (5) 
69 (8) 
 
 
0.035 
55 (17) 
81 (4) 
70 (12) 
 
 
0.160 
Platelet count  <400 x109 
                        >400 x109 
122 (73) 
45 (27) 
65 (5) 
57 (8) 
 
0.084 
81 (4) 
70 (7) 
 
0.020 
Neutrophil/ lymphocyte ratio  
                                    <5:1 
                                    >5:1 
 
129 (77) 
38 (23) 
 
67 (5) 
48 (8) 
 
 
0.047 
 
82 (4) 
66 (8) 
 
 
0.056 
Platelet/ lymphocyte ratio 
                                   <150:1 
                                   >150:1  
 
40 (24) 
127 (76) 
 
62 (8) 
63 (5) 
 
 
0.611 
 
74 (8) 
80 (4) 
 
 
0.719 
Bilirubin  <22 µmol/L 
                >22 µmol/L 
215 (96) 
9 (4) 
61 (4) 
40 (18) 
 
0.379 
74 (3) 
74 (16) 
 
0.910 
Aspartate transaminase  <50 U/L 
                                       >50 U/L  
223 (99) 
1 (1) 
60 (4) 
100 (0) 
 
0.502 
74 (3) 
100 (0) 
 
0.591 
Alanine transaminase  <50 U/L 
                                    >50 U/L 
223 (99) 
1 (1) 
60 (4) 
100 (0) 
 
0.497 
74 (3) 
100 (0) 
 
0.591 
Alkaline phosphatase  < 200 U/L 
                                    > 200 U/L 
123 (55) 
101 (45) 
55 (5) 
45 (5) 
 
0.037 
80 (4) 
67 (5) 
 
0.060 
γ-glutamyl transferase 
<55U/L (men), <35U/L (females) 
>55U/L (men), >35U/L (females) 
 
175 (79) 
50 (21) 
 
63 (4) 
53 (7) 
 
 
0.054 
 
76 (3) 
70 (7) 
 
 
0.324 
Globulin  >22g/L 
                <22g/L 
207 (94) 
14 (6) 
60 (4) 
62 (14) 
 
0.999 
75 (3) 
73 (14) 
 
0.756 
Calcium Adjusted 
               >2.5mmol/L 
               <2.5mmol/L 
 
190 (97) 
6 (3) 
 
61 (4) 
50 (20) 
 
 
0.418 
 
74 (3) 
82 (16) 
 
 
0.874 
mGlasgow Prognostic Score 
  Low Risk (0) 
  Intermediate (1) 
  High Risk (2) 
 
143 (57) 
102 (33) 
42 (10) 
 
74 (4) 
56 (5) 
28 (7) 
 
 
 
<0.001 
 
83 (3) 
70 (5) 
46 (9) 
 
 
 
<0.001 
Table 3:  Tumour and patient related factors and relationship with cancer specific survival in 
colon cancer.  Multivariate analysis of significant variables (P<0.01). 
 
 Overall Survival  Cancer Specific Survival 
Tumour Related Factors (n=287) Hazard ratio 
(95% CI) 
P-value Hazard ratio 
(95% CI) 
P-value 
Dukes Stage  
    (A/ B/ C) 
 
19/ 149/ 119 
 
1.51 (0.93-2.48) 
 
0.099 
 
3.01 (1.50-6.06) 
 
0.002 
Extramural Vascular Invasion   
    (absent/ present) 
 
188/ 19 
 
2.01 (1.14-3.55) 
 
0.016 
 
3.16 (1.53-6.58) 
 
0.002 
Peritoneal Involvement 
    (absent/ present) 
 
205/ 82 
 
 
 
0.424 
 
 
 
0.262 
Margin Involvement 
    (absent/ present) 
 
259/ 28 
 
2.25 (0.93-5.45) 
 
0.072 
  
0.410 
Lymph node ratio 
   (0/ 0.01-0.24/ 0.25-0.49/ >0.5) 
 
166/ 78/ 32/ 11 
 
 
 
0.869 
 
 
0.832 
 
  
 
 
 
Patient Related Factors      
Age  
    (<65/ 65-75/ >75years) 
 
85/ 87/ 115 
 
1.91 (1.34-2.72) 
 
<0.001 
 
 
 
0.110 
 
White Cell Count 
    (<8.5/ 8.5-11 >11x109) 
 
98/ 45/ 24 
  
0.607 
  
0.878 
mGlasgow Prognostic Score 
    (0/ 1/ 2) 
 
143/ 102/ 42 
 
1.73 (1.18-2.55) 
 
0.005 
 
1.96 (1.19-3.21) 
 
0.008 
Table 4:  The relationship between an inflammation based prognostic score (mGlasgow 
Prognostic Score) and other patient- related factors in colon cancer patients. 
 
 mGPS 0 
n=143 
mGPS 1 
n=102 
mGPS 2 
n=42 
P value 
Age  Group  
<65/ 65-74/ >75years 
 
51/ 49/ 43 
 
27/ 48/ 27 
 
7/ 10/ 25 
 
<0.001 
Sex   
Male/ Female 
 
65/ 78 
 
47/ 55 
 
21/ 21 
 
0.646 
Haemoglobin 
>13g/d (men), >11.5g/dl (women)/ 
<13g/dl (men)  <11.5g/dl (women) 
 
 
46/ 36 
 
 
16/ 49 
 
 
4/ 16 
 
 
<0.001 
White cell count  
<8.5x109/ 8.5-11x109/ >11x109 
 
60/ 17/ 5  
 
29/ 21/ 15 
 
9/ 7/ 4 
 
0.001 
Neutrophil count   
<7.5x109/ >7.5x109 
 
76/ 6 
 
47/ 18 
 
14/ 6 
 
0.001 
Lymphocyte count 
<1x109/1-3x109/>3x109 
 
6/ 73/ 3 
 
4/ 54/ 7 
 
0/ 16/ 4 
 
0.012 
Platelet count   
<400 x109/ >400 x109 
 
71/ 11 
 
39/ 26 
 
12/ 8 
 
0.001 
Neutrophil-lymphocyte ratio 
<5:1/ >5:1 
 
76/ 6 
 
44/ 21 
 
9/ 11 
 
<0.001 
Platelet-lymphocyte ratio 
<150:1/ >150:1 
 
23/ 59 
 
12/ 53 
 
5/ 15 
 
0.408 
Bilirubin  
<22 µmol/L/  >22 µmol/L 
 
100/ 5 
 
84/ 3 
 
31/ 1 
 
0.610 
Aspartase transaminase  
<50 U/L/ >50 U/L          
 
105/ 0 
 
86/ 1 
 
32/ 0 
 
0.647 
Alanine transaminase  
<50 U/L/ >50 U/L 
 
105/ 0 
 
86/ 1 
 
32/ 0 
 
0.647 
Alkaline phosphatase  
< 200 U/L/ > 200 U/L 
 
69/ 36 
 
43/ 44 
 
11/ 21 
 
0.001 
γ-Glutamyl transferase 
<55U/L (men), <35U/L in  females/ 
>55U/L (men), >35U/L in  females 
 
 
86/ 20 
 
 
68/ 19 
 
 
21/11 
 
 
0.094 
Globulin  
>22/ <22g/L 
 
96/ 7 
 
82/ 4 
 
29/ 3 
 
0.847 
Calcium Adjusted 
>2.5/ <2.5mmol/L 
 
84/ 4 
 
77/ 0 
 
29/ 2 
 
0.884 
